The memo, written by FDA chief medical and scientific officer Vinay Prasad, reviewed 96 pediatric deaths and concluded that ...

Moderna has continued to underperform the Nasdaq Composite over the past year, and analysts remain cautious about the stock’s ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year ...

Moderna (MRNA) slipped about 6% after an FDA official said future vaccine approvals will face tougher scrutiny, a shift tied ...

CHONGQING, CHINA - JULY 29: In this photo illustration, a smartphone displays the logo of Moderna Inc. (NASDAQ: MRNA), a biotechnology company known for its mRNA-based vaccines and therapeutics, in ...

Major U.S. equities indexes lost ground Monday afternoon, as shares of tech and cryptocurrency-related companies pulled back.

Shares of Moderna MRNA were up 4% yesterday after the company announced positive preliminary immunogenicity data from an ongoing phase IV study, which evaluated the updated version of its COVID-19 ...

Shares of Moderna, Inc. (NASDAQ:MRNA) are trading lower Monday following reports suggesting tighter controls on how vaccines gain approval.

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company’s value has increased by approximately $1.2 billion over ...